Literature DB >> 1389519

Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.

M T Nobile1, R Rosso, M R Sertoli, A Rubagotti, M G Vidili, A Guglielmi, M Venturini, L Canobbio, T Fassio, L Gallo.   

Abstract

148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2. 5-FU plus LV produced a higher response rate than 5-FU alone: 23% (5 complete response, 11 partial response) vs. 8% (2 complete response, 4 partial response) (P = 0.03) out of 70 and 72 evaluable patients, respectively. Median survival was 11 months in both groups and median time to progression was not significantly different (P = 0.08). The combined regimen was more toxic than 5-FU alone, as evidenced by (a) a higher percentage of grade 3-4 diarrhoea, 19.5% vs. 8.5% (P = 0.045) and conjunctivitis, 26.5% vs. 5.6% (P = 0.0025); (b) the recording of one toxic death in the combined arm; and (c) the reduction of the median dose intensity of 5-FU actually delivered during the first 2 months of treatment. We conclude that 5-FU plus LV at a price of a higher toxicity is more active than 5-FU alone without improving survival and progression-free survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389519     DOI: 10.1016/0959-8049(92)90013-r

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 3.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

4.  FIVB plus GM-CSF in metastatic colorectal cancer.

Authors:  C I Falkson; G Falkson; H C Falkson; A Uys; S Keren-Rosenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.

Authors:  G Fried; M Tsalik; M Stein; J Dale; N Haim
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.